CN1351597A - 抗糖尿病的新型多晶形物、其制备方法和含有它们的药物组合物 - Google Patents
抗糖尿病的新型多晶形物、其制备方法和含有它们的药物组合物 Download PDFInfo
- Publication number
- CN1351597A CN1351597A CN00807705A CN00807705A CN1351597A CN 1351597 A CN1351597 A CN 1351597A CN 00807705 A CN00807705 A CN 00807705A CN 00807705 A CN00807705 A CN 00807705A CN 1351597 A CN1351597 A CN 1351597A
- Authority
- CN
- China
- Prior art keywords
- polymorph
- ethoxy
- phenoxazine
- phenyl
- oxyethyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/38—[b, e]-condensed with two six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB1999/000681 WO2000063191A1 (en) | 1999-04-16 | 1999-04-16 | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
WOPCT/IB99/00681 | 1999-04-16 | ||
IN436/MAS/99 | 1999-04-19 | ||
IN436MA1999 | 1999-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1351597A true CN1351597A (zh) | 2002-05-29 |
Family
ID=26318745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00807705A Pending CN1351597A (zh) | 1999-04-16 | 2000-04-17 | 抗糖尿病的新型多晶形物、其制备方法和含有它们的药物组合物 |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1171430A1 (bg) |
CN (1) | CN1351597A (bg) |
AU (1) | AU3831300A (bg) |
BG (1) | BG106022A (bg) |
BR (1) | BR0010683A (bg) |
CA (1) | CA2370401A1 (bg) |
CZ (1) | CZ20013711A3 (bg) |
EE (1) | EE200100529A (bg) |
HR (1) | HRP20010748A2 (bg) |
HU (1) | HUP0200758A3 (bg) |
IL (1) | IL145958A0 (bg) |
MX (1) | MXPA01010472A (bg) |
NO (1) | NO20015016L (bg) |
PL (1) | PL351492A1 (bg) |
RU (1) | RU2001130883A (bg) |
TR (1) | TR200103851T2 (bg) |
WO (1) | WO2000063192A1 (bg) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1263458B1 (en) | 2000-03-08 | 2005-11-16 | Novo Nordisk A/S | Lowering serum cholesterol |
US6897199B2 (en) * | 2001-02-05 | 2005-05-24 | Dr. Reddy's Laboratories Ltd. | Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds |
JP4563675B2 (ja) | 2001-10-12 | 2010-10-13 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 置換ピペリジン類、およびヒスタミンh3受容体関連疾患の治療のためのその使用 |
RU2374236C2 (ru) | 2001-12-21 | 2009-11-27 | Ново Нордиск А/С | Амидные производные в качестве активаторов gk |
ATE347550T1 (de) * | 2002-04-19 | 2006-12-15 | Faes Farma Sa | Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure |
BR0312023A (pt) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
WO2004101505A1 (en) | 2003-05-14 | 2004-11-25 | Novo Nordisk A/S | Novel compounds for treatment of obesity |
RU2381233C2 (ru) | 2003-09-30 | 2010-02-10 | Ново Нордиск А/С | Агонисты рецептора меланокортина |
JP4865565B2 (ja) | 2003-12-09 | 2012-02-01 | ノヴォ ノルディスク アー/エス | Glp−1アゴニストを用いた食物選択の制御 |
MXPA06007667A (es) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
EP1758856A2 (en) | 2004-05-04 | 2007-03-07 | Novo Nordisk A/S | Indole derivatives for the treatment of obesity |
JP2008501765A (ja) | 2004-06-11 | 2008-01-24 | ノボ ノルディスク アクティーゼルスカブ | Glp−1アゴニストを用いた薬剤誘発性肥満の中和 |
US8263551B2 (en) | 2004-11-22 | 2012-09-11 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
US8148412B2 (en) | 2004-12-03 | 2012-04-03 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
ATE536344T1 (de) | 2005-07-04 | 2011-12-15 | High Point Pharmaceuticals Llc | Histamine h3 receptor antagonisten |
US7884210B2 (en) | 2005-07-14 | 2011-02-08 | Novo Nordisk A/S | Ureido-thiazole glucokinase activators |
EP1910317B1 (en) | 2005-07-20 | 2013-07-03 | Eli Lilly And Company | 1-amino linked compounds |
EP1951658B1 (en) | 2005-11-17 | 2012-09-26 | Eli Lilly & Company | Glucagon receptor antagonists, preparation and therapeutic uses |
JP2009531376A (ja) | 2006-03-28 | 2009-09-03 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | ヒスタミンh3受容体活性を有するベンゾチアゾール |
ES2375872T3 (es) | 2006-05-29 | 2012-03-07 | High Point Pharmaceuticals, Llc | 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperacin-1-il)-piridacina, sus sales y solvatos, y su uso como antagonista del receptor h3 de la histamina. |
ATE538109T1 (de) | 2006-11-15 | 2012-01-15 | High Point Pharmaceuticals Llc | Neue für die behandlung von obesitas und diabetes geeignete 2-(2-hydroxyphenyl)benzothiadiazine |
WO2008059026A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
CA2675111C (en) | 2007-01-11 | 2016-04-05 | Novo Nordisk A\S | Urea glucokinase activators |
JP2010013472A (ja) * | 2009-09-09 | 2010-01-21 | Faes Farma Sa | 4−[2−[1−(2−エトキシエチル)−1H−ベンズイミダゾール−2−イル]−1−ピペリジニル]エチル]−α,α−ジメチルベンゼノ酢酸の多形体 |
BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
US20130012432A1 (en) | 2010-02-26 | 2013-01-10 | Novo Nordisk A/S | Peptides for Treatment of Obesity |
JP6026993B2 (ja) | 2010-03-26 | 2016-11-16 | ノヴォ ノルディスク アー/エス | 新規のグルカゴンアナログ |
WO2012104834A1 (en) | 2011-02-03 | 2012-08-09 | Pharmedica Ltd. | New oral dissolving films for insulin administration, for treating diabetes |
RU2013145013A (ru) | 2011-03-28 | 2015-05-10 | Ново Нордиск А/С | Новые аналоги глюкагона |
RU2610175C2 (ru) | 2011-09-23 | 2017-02-08 | Ново Нордиск А/С | Новые аналоги глюкагона |
US20150004144A1 (en) | 2011-12-02 | 2015-01-01 | The General Hospital Corporation | Differentiation into brown adipocytes |
WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
WO2015185640A1 (en) | 2014-06-04 | 2015-12-10 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
US20200223889A1 (en) | 2017-03-15 | 2020-07-16 | Novo Nordisk A/S | Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor |
US20210221867A1 (en) | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
US5248699A (en) * | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
WO1997027191A1 (en) * | 1996-06-19 | 1997-07-31 | Dr. Reddy's Research Foundation | Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation |
IN182496B (bg) * | 1996-02-20 | 1999-04-17 | Reddy Research Foundation | |
GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
FR2746099B1 (fr) * | 1996-03-13 | 1998-04-30 | Procede ameliore pour la preparation de derives de l'acide 3-(10-phenothiazyl)-propanoique ou 3-(10-phenoxazyl)-propanoique | |
WO1999019313A1 (en) * | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
EP1051403A1 (en) * | 1998-01-29 | 2000-11-15 | Dr. Reddy's Research Foundation | Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
EP1082313A1 (en) * | 1998-05-27 | 2001-03-14 | Dr. Reddy's Research Foundation | Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
-
2000
- 2000-04-17 IL IL14595800A patent/IL145958A0/xx unknown
- 2000-04-17 CN CN00807705A patent/CN1351597A/zh active Pending
- 2000-04-17 AU AU38313/00A patent/AU3831300A/en not_active Abandoned
- 2000-04-17 TR TR2001/03851T patent/TR200103851T2/xx unknown
- 2000-04-17 HU HU0200758A patent/HUP0200758A3/hu unknown
- 2000-04-17 WO PCT/IB2000/000470 patent/WO2000063192A1/en active Search and Examination
- 2000-04-17 EE EEP200100529A patent/EE200100529A/xx unknown
- 2000-04-17 EP EP00917222A patent/EP1171430A1/en not_active Withdrawn
- 2000-04-17 CZ CZ20013711A patent/CZ20013711A3/cs unknown
- 2000-04-17 BR BR0010683-6A patent/BR0010683A/pt not_active IP Right Cessation
- 2000-04-17 CA CA002370401A patent/CA2370401A1/en not_active Abandoned
- 2000-04-17 MX MXPA01010472A patent/MXPA01010472A/es unknown
- 2000-04-17 PL PL00351492A patent/PL351492A1/xx not_active Application Discontinuation
- 2000-04-17 RU RU2001130883/04A patent/RU2001130883A/ru unknown
-
2001
- 2001-10-15 NO NO20015016A patent/NO20015016L/no not_active Application Discontinuation
- 2001-10-15 HR HR20010748A patent/HRP20010748A2/hr not_active Application Discontinuation
- 2001-10-16 BG BG106022A patent/BG106022A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0200758A2 (hu) | 2002-07-29 |
TR200103851T2 (tr) | 2002-04-22 |
NO20015016D0 (no) | 2001-10-15 |
MXPA01010472A (es) | 2002-05-06 |
BG106022A (bg) | 2002-04-30 |
CZ20013711A3 (cs) | 2002-07-17 |
NO20015016L (no) | 2001-12-11 |
HRP20010748A2 (en) | 2003-02-28 |
AU3831300A (en) | 2000-11-02 |
HUP0200758A3 (en) | 2003-07-28 |
EP1171430A1 (en) | 2002-01-16 |
PL351492A1 (en) | 2003-04-22 |
CA2370401A1 (en) | 2000-10-26 |
WO2000063192A1 (en) | 2000-10-26 |
BR0010683A (pt) | 2003-07-01 |
IL145958A0 (en) | 2002-07-25 |
EE200100529A (et) | 2002-12-16 |
RU2001130883A (ru) | 2004-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1351597A (zh) | 抗糖尿病的新型多晶形物、其制备方法和含有它们的药物组合物 | |
CN100344616C (zh) | 用于治疗代谢失调的化合物 | |
CN1046722C (zh) | 杂环化合物及其制备和应用 | |
CN1280574A (zh) | 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物 | |
CN1750758A (zh) | 用于治疗代谢紊乱的化合物 | |
CN1221417A (zh) | 具有抗糖尿病、降低血脂、抗高血压性能的噻唑烷二酮化合物,其制备方法及其药物组合物 | |
CN1489463A (zh) | 阿托伐他汀半钙的新晶型及其制备方法,以及其它晶型的新制备方法 | |
CN1311767A (zh) | 治疗代谢性疾病的糖皮质激素和甲状腺激素受体的配体 | |
CN88101642A (zh) | 哌嗪基-杂环化合物 | |
CN1266129C (zh) | 具有降血脂和降低血中胆固醇活性的新化合物、其制备方法和含有它们的药物组合物 | |
CN1774244A (zh) | 用于治疗代谢紊乱的化合物 | |
CN86106428A (zh) | 抗肿瘤方法及其化合物 | |
CN1355790A (zh) | 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法 | |
CN1780614A (zh) | 用于治疗代谢紊乱的化合物 | |
CN1358175A (zh) | 嘧啶酮化合物 | |
CN1026234C (zh) | 用于降血糖的噻唑烷二酮衍生物的制备方法 | |
CN1777576A (zh) | 用于治疗代谢紊乱的化合物 | |
CN87102891A (zh) | 硫化内酰胺-n-乙酸衍生物的生产及使用 | |
CN1968687A (zh) | 预防和治疗代谢性骨病的含有α-芳基甲氧基丙烯酸酯衍生物的药物组合物 | |
CN101039921A (zh) | 3-[5-氯-4-[(2,4-二氟苄基)氧基]-6-氧代嘧啶-1(6h)-基]-n-(2-羟乙基)-4-甲基苯甲酰胺的晶形 | |
CN1728992A (zh) | 具有降低血清葡萄糖和降低血清脂质活性的α-苯硫基羧酸和α-苯氧基羧酸的用途 | |
CN1205704A (zh) | 2,7-取代的八氢-吡咯并[1,2-a]吡嗪衍生物 | |
CN1257893C (zh) | 具有优异降糖降酯活性的芳烷基氨基酸类ppar全激活剂 | |
CN1310912C (zh) | 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮甲磺酸盐 | |
CN1849306A (zh) | 基质金属蛋白酶抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: REDDY LAB CO LTD Free format text: FORMER OWNER: DR. LEI DI RESEARCH FOUNDATION Effective date: 20020524 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20020524 Address after: Hyderabad Applicant after: Dr. Reddy's Research Foundation Address before: Andhra Pradesh Applicant before: Dr. Reddy's research Foundation |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |